TRML NASDAQ
Tourmaline Bio, Inc.
1W: +0.0%
1M: +0.2%
3M: +120.5%
1Y: +74.8%
3Y: +574.8%
$47.98
Last traded 2025-10-30 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$1.2B
52W Range11.56-48.27
Volume783,730
Avg Volume925,778
Beta1.58
Dividend—
Analyst Ratings
Company Info
CEOSandeep C. Kulkarni
Employees74
SectorHealthcare
IndustryBiotechnology
IPO Date2021-05-07
Websitetourmalinebio.com
27 West 24th Street
New York City, NY 10010
US
New York City, NY 10010
US
646-481-9832
About Tourmaline Bio, Inc.
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.
Latest News
No recent news
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| SIEGALL CLAY B | D-Return | 16,800 | $18.73 | 2025-10-28 |
| SIEGALL CLAY B | D-Return | 15,000 | $13.91 | 2025-10-28 |
| SIEGALL CLAY B | D-Return | 20,000 | $18.55 | 2025-10-28 |
| Thiara Parvinder | D-Return | 16,800 | $18.73 | 2025-10-28 |
| Thiara Parvinder | U-Tender | 83,782 | $48.00 | 2025-10-28 |